A single intravenous dose of EMEND for Injection was shown to be superior to placebo when either were combined with other anti-vomiting agents for protection against CINV in patients receiving ...

The FDA has expanded the approval of Emend's indication for chemotherapy-induced nausea and vomiting. The FDA has approved Emend (aprepitant capsules) in combination with other antiemetic agents for ...

Aprepitant 125mg; per pouch; pwd for oral susp after reconstitution. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors with little or no affinity for ...

Fosaprepitant dimeglumine (prodrug of aprepitant) 150mg/vial; lyophilized pwd for IV infusion after reconstitution and dilution; contains polysorbate 80. <6mos or <6kg: not recommended. Give with 5-HT ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio LAS VEGAS — Oral Emend improved ...

Merck & Co has been given the go ahead in the USA to market its Emend drug to treat nausea and vomiting in patients who undergo surgery, increasing the number of patients eligible to receive treatment ...

Merck & Co’s nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study. The 1,000-patient trial ...

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New ...

Merck & Co won US approval to expand the use of its anti-nausea drug Emend yesterday, which could add sales momentum to a product that has taken a while to get going. Merck & Co won US approval to ...